Startup profile · funding coverage
Yingjiexin Medical funding, valuation and investors
Chinese manufacturer of precision injection pens and self-administered drug-delivery systems.
Verified company research · funding, investors and latest developments
Keep track of Yingjiexin Medical
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B (November 2 disclosure)
About $30 million (USD equivalent) · November 2, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$30M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Shanghai, China
Investors in latest funding
Lead: CICC Capital
Other: Zhuhai Science and Technology Industry Group , Cornerstone Capital , Qiming Venture Partners
Overview
Shanghai Yingjiexin Medical Technology makes prefilled and reusable injection pens and autoinjectors. Capital is directed to manufacturing scale, device development, overseas registration and global commercial delivery.
Why Yingjiexin Medical is interesting
About $30M USD-equivalent Series B financing disclosed November 2 to expand injection pens and delivery devices for biologics and GLP-1 medicines.
Funding history (newest first)
Series B (November 2 disclosure)
2026-11-02 About $30 million (USD equivalent)- CICC Capital (lead)
- Zhuhai Science and Technology Industry Group (participant)
- Cornerstone Capital (participant)
- Qiming Venture Partners (participant)
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.